Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The DYT1 phenotype and guidelines for diagnostic testing.

S B Bressman1, C Sabatti, D Raymond

  • 1Department of Neurology, Beth Israel Medical Center, New York, NY 10003, USA.

Neurology
|May 10, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease.

The open neuroimaging journal·2009
Same author

Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology.

Experimental neurology·2009
Same author

Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles.

Journal of neurology, neurosurgery, and psychiatry·2009
Same author

Imaging the impact of genes on Parkinson's disease.

Neuroscience·2009
Same author

The D216H variant in the DYT1 gene: a susceptibility factor for dystonia in familial cases?

Neurology·2009
Same author

Somatosensory processing in a German family with PINK1 mutations: its potential role in Parkinson disease.

Journal of neurology, neurosurgery, and psychiatry·2009

Diagnostic testing for the DYT1 GAG deletion is recommended for primary torsion dystonia (PTD) patients with onset before age 26. This guideline aids in identifying carriers and understanding dystonic features in Ashkenazi Jewish and non-Jewish populations.

Area of Science:

  • Genetics
  • Neurology
  • Medical Diagnostics

Background:

  • Primary torsion dystonia (PTD) is a neurological disorder with genetic underpinnings.
  • The DYT1 GAG deletion is a significant genetic marker associated with PTD, particularly in certain populations.
  • Understanding the clinical spectrum and diagnostic criteria for DYT1-associated PTD is crucial for effective management.

Purpose of the Study:

  • To establish diagnostic testing guidelines for the DYT1 GAG deletion in primary torsion dystonia (PTD) patients.
  • To define the range of dystonic features observed in individuals carrying the DYT1 GAG deletion.
  • To compare diagnostic utility between Ashkenazi Jewish (AJ) and non-Jewish (NJ) populations.

Main Methods:

  • Screening of 267 individuals with PTD for DYT1 GAG deletion status using PCR amplification.

Related Experiment Videos

  • Comparison of dystonia features between DYT1 GAG deletion carriers and non-carriers to develop a predictive classification scheme.
  • Assessment of clinical features in genetically ascertained carriers and analysis of differences between AJ and NJ patients.

    • Main Results:

    • An optimal classification algorithm for clinically ascertained carriers involved disease onset before age 24 in a limb, achieving 95% sensitivity and 80% specificity.
    • The classification scheme showed high sensitivity (96%) and specificity (88%) in the AJ group but lower specificity (69%) in the NJ group.
    • Using age 26 as a cut-off with any onset site detected 100% of clinically ascertained carriers but reduced specificity to 54% overall (63% AJ, 43% NJ).
    • Genetically ascertained carriers exhibited onset up to age 44, with no significant differences between AJ and NJ groups, except for a higher proportion of NJ carriers presenting with leg onset and widespread disease.

    Conclusions:

    • Diagnostic DYT1 testing combined with genetic counseling is advised for PTD patients with onset before age 26.
    • This criterion identifies 100% of clinically ascertained carriers, though specificity varies (43%-63%).
    • Testing may be beneficial for patients with onset after age 26 if they have an affected relative with early onset.